Impact of Age-related Macular Degeneration on Daily Living Activitie

Age-Related Macular Degeneration Clinical Trial

— AMDAY  

Official title:

Validation of Standardized Tasks and Questionnaires to Evaluate and Understand the Impact of Age-related Macular Degeneration on Daily Living Activitie

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06333873
• Other study ID #: P22-09
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2024
• Est. completion date: June 2029

Study information

• Verified date: March 2024
• Source: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
• Contact: Nabil BROUK
• Phone: +33140021738
• Email: nbrouk[@]15-20.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The complex and variable course of age-related diseases makes it all the more necessary to carry out personalised, reasoning-based examinations to improve the personalised assessment and management of AMD. However, functional assessment of AMD is most often based solely on visual acuity, and classifications of AMD are based solely on structural markers. There is therefore a need to improve the detection and functional assessment of this vision-threatening eye disease, by complementing and extending the standard assessments of clinical outcomes (COA)

Description:

Prospective, longitudinal, interventional, exploratory, non-randomised, single-centre study, including healthy volunteers and patients with Age-Related Macular Degeneration

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: June 2029
• Est. primary completion date: June 2029
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• General criteria for healthy volunteers and AMD patients:
• Male / Female participant,
• Age = 50 at inclusion,
• Able and willing to provide written informed consent and comply with the study protocol, visits and assessments,
• Quality of AO imaging as assessed by rtx1 camera, ? deemed adequate according to the study physician,
• Membership of a social security scheme or beneficiary of such a scheme.
• Specific criteria for the AMD group:
• Geriatric Depression Scale (GDS) questionnaire score = 10 A COGEVIS questionnaire score = 24/30
• Visual acuity greater than 4/10ths
• General criteria for healthy volunteers:
• No detectable visual pathologies
• Best monocular visual acuity (corrected to 100% of the contrast) = 8/10ths before age 70 and = 6/10ths after.
• MMSE score = 20
• Specific criteria for the group of healthy volunteers with central microdrusens:
• No detectable visual pathologies other than the presence of central microdrusens.
• Best monocular visual acuity (corrected to 100% contrast) = 8/10th before age 70 and = 6/10th after.
• MMSE score = 20

Exclusion Criteria:

• Pregnant, parturient or breast-feeding women,
• Subjects taking medication likely to cause motor, visual, vestibular or cognitive disorders (PSA, neuroleptics, etc.) or who could interfere with the study examinations cannot be included in this study,
• Environmental opacity or eye movement disorders (nystagmus) which, in the opinion of the investigator, interfere with the quality of retinal imaging data.
• Any concomitant intraocular condition in the study eye (e.g. glaucoma or cataract) that, in the opinion of the investigator, would require surgical intervention during the study to prevent or treat vision loss that may result from this condition or affect the interpretation of study results,
• Known systemic disease which, in the opinion of the investigator, would preclude active participation in the study,
• Participation in any other therapeutic study evaluating a drug,
• Cognitively impaired subjects, illiterate subjects and subjects who do not speak the national language.
• Subjects with dyslexic reading disorders,
• Subjects subject to a reinforced protection measure or legal safeguard (curatorship, guardianship).

Related Conditions & MeSH terms

• Age-Related Macular Degeneration
• Macular Degeneration

Intervention

Other:
• patient-reported outcome
Performance of real-life tests and tasks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Validity of criteria	Number of patients with capacity of discrimintaion compared to healthy volunteers.; ROC (receiver operating characteristic curve), which illustrates the diagnostic capacity of a binary classification system as a function of the variation in its discrimination threshold. The ROC curve is created by plotting the rate of true positives versus the false-positive rate for different thresholds. The index used to characterize a test's of a test is the air under the curve	26 month
Primary	Validity of content	number of paticipants with capacity to execute questionnaires and daily real-life task	26 month
Primary	Reproducibility of results	Number of patients able to reproduce the same performance tests	26 month